• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

    4/17/25 7:30:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACXP alert in real time by email

    STATEN ISLAND, N.Y., April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Indian Patent Office in March 2025. This patent relates to DNA Polymerase IIIC Inhibitors, including compositions-of-matter. This is the latest in the series of granted patents and pending patent applications that Acurx has filed to protect its proprietary technologies in the field of antimicrobials. To date, Acurx has obtained three U.S. patents, one Israeli patent, one Japanese patent, and now one Indian patent, in each case, which cover the ACX-375C program, relating to DNA Polymerase IIIC Inhibitors, with other country-level filings in process.

    Robert J. DeLuccia, Executive Chairman of Acurx, stated: "Achieving this patent in India adds to our growing number of countries as we further develop our innovative, AI-supported drug discovery platform of second-generation DNA pol IIIC inhibitors". He added: "While our lead DNA pol IIIC inhibitor is Phase 3-ready for oral treatment of C. difficile Infection, our second generation compounds in our program are systemically absorbed for potential oral and parenteral use in multiple clinical settings for treatment of infections caused by gram-positive bacteria, such as Staphylococcus aureus, including MRSA, VRE and DRSP, and  B. anthracis or anthrax, a Bioterrorism Category A Threat-Level pathogen."

    About Acurx Pharmaceuticals, Inc.

    Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials as soon as possible.  The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.

    To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com

    Forward-Looking Statements

    Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.

    Investor Contact:

    Acurx Pharmaceuticals, Inc.

    David P. Luci, President & CEO

    Tel: 917-533-1469

    Email: [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/indian-patent-office-grants-acurx-patent-for-dna-polymerase-iiic-inhibitors-302431139.html

    SOURCE Acurx Pharmaceuticals, Inc.

    Get the next $ACXP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACXP

    DatePrice TargetRatingAnalyst
    11/29/2021$12.00Buy
    Maxim Group
    More analyst ratings

    $ACXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Acurx Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      11/29/21 8:33:36 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Acurx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

      2/14/24 2:39:21 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

      SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

      2/14/23 11:59:03 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

      SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

      2/14/23 11:52:45 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Shawah Robert G.

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      2/6/25 5:47:58 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Luci David P

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      2/6/25 5:46:58 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Deluccia Robert J

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      2/6/25 5:45:47 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

      STATEN ISLAND, N.Y., May 13, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2025.   Highlights of the first quarter ended March 31, 2025, or in some cases shortly thereafter, include: In January 2025, the Company announced it had closed a $2.5 million registered direct offering priced at the market under Nasdaq rules.Also in January 2025, we announced that we received positive regulatory guidance from the European Medicines Agency (E

      5/13/25 7:01:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, May 13, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-790-1503; Conference

      4/30/25 7:30:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

      STATEN ISLAND, N.Y., April 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals (NASDAQ:ACXP) (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections today announced that David P. Luci, President & Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase on Wednesday, May 21, 2025, at 9:00 a.m. ET. The Company's lead antibiotic candidate, ibezapolstat (IBZ), is ready to advance to international Phase 3 clinical trials for treatment of patients with C. difficile infection (CDI). A live webcast of the presentation can be found here. A replay o

      4/28/25 7:30:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    SEC Filings

    See more
    • SEC Form S-1 filed by Acurx Pharmaceuticals Inc.

      S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/21/25 4:16:04 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Acurx Pharmaceuticals Inc.

      D - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/20/25 3:32:14 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Acurx Pharmaceuticals Inc.

      PRE 14A - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/19/25 4:05:41 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Scodari Joseph C bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 800% to 27,708 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:32:30 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sailer Carl bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 22% to 137,183 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:31:59 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Luci David P bought $50,000 worth of shares (49,261 units at $1.01), increasing direct ownership by 5% to 1,097,458 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:31:33 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Financials

    Live finance-specific insights

    See more
    • Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, May 13, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-790-1503; Conference

      4/30/25 7:30:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., Feb. 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its fourth quarter and full year 2024 financial results on Tuesday, March 18, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, March 18, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-79

      2/28/25 8:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

      STATEN ISLAND, N.Y., Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2024. Highlights of the third quarter ended September 30, 2024, or in some cases shortly thereafter, include: In July 2024, results from the ibezapolstat (IBZ) Phase 2 clinical trial in patients with C. difficile Infection (CDI) were presented at the 17th Biennial Congress of the Anaerobe Society of the Americas by Taryn A. Eubank, PharmD, BCIDP,

      11/13/24 7:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care